To obtain a composition for a transnasal administration having an extremely low occurrence rate of adverse effects as compared with oral administration preparations, exhibiting quick exhibition of analgesic effect, and in addition, excellent in view of bioavailability.

This composition for the transnasal absorption is obtained by dispersing and attaching for bonding an effective amount of an opioid analgesic uniformly in a carrier consisting of calcium carbonate and/or calcium phosphate having ≤500 μm mean particle diameter. More preferably, the opioid analgesic is morphine hydrochloride, morphine sulfate, a blended preparation of morphine hydrochloride/atropine sulfate, fentanyl, fentanyl citrate, a blended preparation of troperidol/fentanyl citrate or buprenorfin hydrochloride, and the carrier is calcium carbonate in the composition for transnasal absorption.